Cellular targeting in autoimmunity.

Published

Journal Article (Review)

Many biologic agents that were first approved for the treatment of malignancies are now being actively investigated and used in a variety of autoimmune diseases such as rheumatoid arthritis (RA), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, systemic lupus erythematosus (SLE), and Sjogren's syndrome. The relatively recent advance of selective immune targeting has significantly changed the management of autoimmune disorders and in part can be attributed to the progress made in understanding effector cell function and their signaling pathways. In this review, we will discuss the recent FDA-approved biologic therapies that directly target immune cells as well as the most promising investigational drugs affecting immune cell function and signaling for the treatment of autoimmune disease.

Full Text

Duke Authors

Cited Authors

  • Rogers, JL; Serafin, DS; Timoshchenko, RG; Tarrant, TK

Published Date

  • December 2012

Published In

Volume / Issue

  • 12 / 6

Start / End Page

  • 495 - 510

PubMed ID

  • 23054625

Pubmed Central ID

  • 23054625

Electronic International Standard Serial Number (EISSN)

  • 1534-6315

Digital Object Identifier (DOI)

  • 10.1007/s11882-012-0307-y

Language

  • eng

Conference Location

  • United States